A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT06115135 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma in Relapse
Multiple Myeloma, Refractory

Interventions

DRUG: Venetoclax

Sponsor

Oncotherapeutics